Buscar
Resultados de la búsqueda
- Nimotuzumab en tumores inoperables de esófago epitelial-Fase IV
-
... Seguridad y efectividad del Nimotuzumab en tumores inoperables de esófago de origen epitelial. Fase IV ... Grupo experimental (Nimotuzumab). Infusión intravenosa de 200 mg del producto en esquema de ...
Ensayos Clínicos - CIM - 23/07/2020 - 6:39pm
- Nimotuzumab-pancreatic cancer-adults-Phase IV.
-
... Evaluation of the safety and effectiveness of CIMAher® (Nimotuzumab) in the treatment of patients with locally advanced adenocarcinoma ... Group I (experimental): 2 year treatment with Nimotuzumab 400 mg once a week (intravenous) until discontinuation criteria, in ...
Clinical Trials - CIM - 23/07/2020 - 5:14pm
- Nimotuzumab-cáncer de páncreas-adultos-Fase IV
-
... Evaluación de la seguridad y efectividad del CIMAher® (Nimotuzumab) en el tratamiento de pacientes con adenocarcinoma de páncreas ... claves: Nimotuzumab, cáncer de páncreas localmente avanzado, irresecable, ...
Ensayos Clínicos - CIM - 23/07/2020 - 4:50pm
- Study of the mechanism of action of Nimotuzumab in patients with head and neck tumors
-
... Use of monoclonal antibody Nimotuzumab and radio-chemotherapy in the treatment of patients with locally ... Experimental group: RadioChemotherapy + Anti-EGFR mAb Nimotuzumab at 200 mg intravenously. The Nimotuzumab will have an induction ...
Clinical Trials - CIM - 17/02/2017 - 4:24pm
- Estudio del mecanismo de acción del Nimotuzumab en pacientes con tumores de cabeza y cuello
-
... Uso del anticuerpo monoclonal Nimotuzumab y radio-quimioterapia en el tratamiento de pacientes con cáncer de ... claves: nimotuzumab, ADCC, CTL, células T reguladoras, cross-presentación, cáncer de ...
Ensayos Clínicos - CIM - 17/02/2017 - 4:24pm
- NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer
-
... Immunotherapy with NGcGM3/VSSP and nimotuzumab in metastatic triple negative breast cancer patients. Phase I/II ... months Group 2 (experimental): Oncospecific treatment + nimotuzumab with the first six weekly doses of 200 mg (intravenous), then one ...
Clinical Trials - CIM - 22/12/2016 - 11:39am
- NGcGM3/VSSP y nimotuzumab en pacientes con cáncer de mama triple negativo
-
... “Inmunoterapia con NGcGM3/VSSP y nimotuzumab en pacientes con cáncer de mama triple negativo metastásico”. ... NGcGM3/VSSP, nimotuzumab, cáncer de mama triple negativo ...
Ensayos Clínicos - CIM - 22/12/2016 - 11:38am
- Effectiveness and Safety of Nimotuzumab for the treatment of patients with glioma tumors
-
... of the Effectiveness and Safety of Monoclonal Antibody HR3(Nimotuzumab)for the treatment of patients with high grade glioma tumors. ... Nimotuzumab: 200 mg intravenous (antecubital vein) in a volume of 250 ml ...
Clinical Trials - CIMAB - 17/07/2015 - 10:47am
- Efectividad y seguridad del Nimotuzumab en pacientes con tumores gliales.
-
... la efectividad y seguridad del anticuerpo monoclonal hR3(Nimotuzumab)para el tratamiento de pacientes con tumores gliales de alto grado ... claves: Nimotuzumab,Tumores Gliales. ...
Ensayos Clínicos - CIMAB - 17/07/2015 - 10:47am
- Study of intensive pediatric pharmacovigilance of nimotuzumab for the treatment of malignant glioma tumors.
-
... pediatric pharmacovigilance of monoclonal antibody nimotuzumab for the treatment of malignant glioma tumors ... Scheme 1: Surgery + Radiotherapy (54-60 Gy) + Nimotuzumab + Chemotherapy (Cisplatin + Cyclophosphamide, procarbazine; ...
Clinical Trials - CIMAB - 14/08/2014 - 4:34pm